Výsledky vyhledávání - "Kimberly W, Hart"

Akademický článek

Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial

Autor: Alexander M. Kaizer, Nathan I. Shapiro, Jessica Wild, Samuel M. Brown, B. Jessica Cwik, Kimberly W. Hart, Alan E. Jones, Michael S. Pulia, Wesley H. Self, Clay Smith, Stephanie A. Smith, Patrick C. Ng, B. Taylor Thompson, Todd W. Rice, Christopher J. Lindsell, Adit A. Ginde

Publikováno v: International Journal of Infectious Diseases, Vol 128, Iss , Pp 223-229 (2023)

Objectives: Effective and widely available therapies are still needed for outpatients with COVID-19. We aimed to evaluate the efficacy and safety of lopinavir/ritonavir (LPV/r) for early treatment of non-hospitalized individuals diagnosed with COVID-

Externí odkaz: https://doaj.org/article/a331a0a5b9994c778243d39b26885423

Zobrazit plný text záznamu

Akademický článek

Trial of Early Antiviral Therapies during Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19: a summary of the protocol and analysis plan for a decentralized randomized controlled trial

Autor: Alexander M. Kaizer, Jessica Wild, Christopher J. Lindsell, Todd W. Rice, Wesley H. Self, Samuel Brown, B. Taylor Thompson, Kimberly W. Hart, Clay Smith, Michael S. Pulia, Nathan I. Shapiro, Adit A. Ginde

Publikováno v: Trials, Vol 23, Iss 1, Pp 1-12 (2022)

Abstract Background Coronavirus disease 2019 (COVID-19) has a heterogeneous outcome in individuals from remaining asymptomatic to death. In a majority of cases, mild symptoms are present that do not require hospitalization and can be successfully tre

Externí odkaz: https://doaj.org/article/1bf004d8143d460882da4454efee07ce

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Clarifying the volume of estimated need for public health and prevention services within an emergency department population

Autor: Rachel M. Ancona, David Habib, Kiran A. Faryar, Andrew H. Ruffner, Kimberly W. Hart, Michael S. Lyons

Publikováno v: Journal of the American College of Emergency Physicians Open, Vol 1, Iss 5, Pp 845-851 (2020)

Abstract Objectives Emergency departments (EDs) are called to implement public health and prevention initiatives, such as infectious disease screening. The perception that ED resources are insufficient is a primary barrier. Resource needs are general

Externí odkaz: https://doaj.org/article/898bcc5b6146439b9c4062f5af415402

Zobrazit plný text záznamu

Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States

Autor: Caitlin Turbyfill, Katherine Adams, Mark W. Tenforde, Nancy L. Murray, Manjusha Gaglani, Adit A. Ginde, Tresa McNeal, Shekhar Ghamande, David J. Douin, H. Keipp Talbot, Jonathan D. Casey, Nicholas M. Mohr, Anne Zepeski, Nathan I. Shapiro, Kevin W. Gibbs, D. Clark Files, David N. Hager, Arber Shehu, Matthew E. Prekker, Anne E. Frosch, Matthew C. Exline, Michelle N. Gong, Amira Mohamed, Nicholas J. Johnson, Vasisht Srinivasan, Jay S. Steingrub, Ithan D. Peltan, Samuel M. Brown, Emily T. Martin, Adam S. Lauring, Akram Khan, Laurence W. Busse, Caitlin C. ten Lohuis, Abhijit Duggal, Jennifer G. Wilson, Alexandra June Gordon, Nida Qadir, Steven Y. Chang, Christopher Mallow, Carolina Rivas, Jennie H. Kwon, Natasha Halasa, James D. Chappell, Carlos G. Grijalva, Todd W. Rice, William B. Stubblefield, Adrienne Baughman, Jillian P. Rhoads, Christopher J. Lindsell, Kimberly W. Hart, Meredith McMorrow, Diya Surie, Wesley H. Self, Manish M. Patel

Publikováno v: Vaccine, vol 40, iss 48

BackgroundTest-negative design (TND) studies have produced validated estimates of vaccine effectiveness (VE) for influenza vaccine studies. However, syndrome-negative controls have been proposed for differentiating bias and true estimates in VE evalu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f3d4d9eebaaa287a091629da3368667
https://doi.org/10.1016/j.vaccine.2022.10.034

Zobrazit plný text záznamu

Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022

Autor: Diya, Surie, Levi, Bonnell, Katherine, Adams, Manjusha, Gaglani, Adit A, Ginde, David J, Douin, H Keipp, Talbot, Jonathan D, Casey, Nicholas M, Mohr, Anne, Zepeski, Tresa, McNeal, Shekhar, Ghamande, Kevin W, Gibbs, D Clark, Files, David N, Hager, Arber, Shehu, Anne P, Frosch, Heidi L, Erickson, Michelle N, Gong, Amira, Mohamed, Nicholas J, Johnson, Vasisht, Srinivasan, Jay S, Steingrub, Ithan D, Peltan, Samuel M, Brown, Emily T, Martin, Akram, Khan, William S, Bender, Abhijit, Duggal, Jennifer G, Wilson, Nida, Qadir, Steven Y, Chang, Christopher, Mallow, Carolina, Rivas, Jennie H, Kwon, Matthew C, Exline, Adam S, Lauring, Nathan I, Shapiro, Natasha, Halasa, James D, Chappell, Carlos G, Grijalva, Todd W, Rice, William B, Stubblefield, Adrienne, Baughman, Kelsey N, Womack, Kimberly W, Hart, Sydney A, Swan, Yuwei, Zhu, Jennifer, DeCuir, Mark W, Tenforde, Manish M, Patel, Meredith L, McMorrow, Wesley H, Self, Carleigh, Samuels

Publikováno v: MMWR. Morbidity and Mortality Weekly Report. 71:1327-1334

The SARS-CoV-2 Omicron variant (B.1.1.529 or BA.1) became predominant in the United States by late December 2021 (1). BA.1 has since been replaced by emerging lineages BA.2 (including BA.2.12.1) in March 2022, followed by BA.4 and BA.5, which have ac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::198a0fb85e6ad0bdec844161784e9cab
https://doi.org/10.15585/mmwr.mm7142a3

Zobrazit plný text záznamu

Ascertainment of vaccination status by self‐report versus source documentation: Impact on measuring COVID‐19 vaccine effectiveness

Publikováno v: Influenza and Other Respiratory Viruses. 16:1101-1111

During the COVID-19 pandemic, self-reported COVID-19 vaccination might facilitate rapid evaluations of vaccine effectiveness (VE) when source documentation (e.g., immunization information systems [IIS]) is not readily available. We evaluated the conc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69db2bb474b04e0b1783a450b9e935cf
https://doi.org/10.1111/irv.13023

Zobrazit plný text záznamu

Plný text ve formátu HTML

Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States

Autor: Nathaniel M, Lewis, Wesley H, Self, Manjusha, Gaglani, Adit A, Ginde, David J, Douin, H, Keipp Talbot, Jonathan D, Casey, Nicholas M, Mohr, Anne, Zepeski, Shekhar A, Ghamande, Tresa A, McNeal, Nathan I, Shapiro, Kevin W, Gibbs, D Clark, Files, David N, Hager, Arber, Shehu, Matthew E, Prekker, Heidi L, Erickson, Michelle N, Gong, Amira, Mohamed, Nicholas J, Johnson, Vasisht, Srinivasan, Jay S, Steingrub, Ithan D, Peltan, Samuel M, Brown, Emily T, Martin, Arnold S, Monto, Akram, Khan, Laurence W, Busse, Caitlin C Ten, Lohuis, Abhijit, Duggal, Jennifer G, Wilson, Alexandra June, Gordon, Nida, Qadir, Steven Y, Chang, Christopher, Mallow, Carolina, Rivas, Hilary M, Babcock, Jennie H, Kwon, Matthew C, Exline, Adam S, Lauring, Natasha, Halasa, James D, Chappell, Carlos G, Grijalva, Todd W, Rice, Jillian P, Rhoads, Ian D, Jones, William B, Stubblefield, Adrienne, Baughman, Kelsey N, Womack, Christopher J, Lindsell, Kimberly W, Hart, Yuwei, Zhu, Katherine, Adams, Manish M, Patel, Mark W, Tenforde

Publikováno v: Clinical Infectious Diseases. 75:S159-S166

Background . Adults in the United States (US) began receiving the adenovirus vector coronavirus disease 2019 (COVID-19) vaccine, Ad26.COV2.S (Johnson & Johnson [Janssen]), in February 2021. We evaluated Ad26.COV2.S vaccine effectiveness (VE) against

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d4efe6f52aace78e5793a53d83a0ad8
https://doi.org/10.1093/cid/ciac439

Zobrazit plný text záznamu

Comparison of mRNA Vaccine Effectiveness against COVID-19-associated Hospitalization by Vaccination Source: Immunization Information Systems, Electronic Medical Records, and Self-Report — IVY Network, February 1*August 31, 2022

Publikováno v: Vaccine.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12f424a47c9fe9246c48d3d6f51a3cb6
https://doi.org/10.1016/j.vaccine.2023.05.028

Zobrazit plný text záznamu

Akademický článek

Prospective Testing and Redesign of a Temporal Biomarker Based Risk Model for Patients With Septic Shock: Implications for Septic Shock Biology

Publikováno v: EBioMedicine, Vol 2, Iss 12, Pp 2087-2093 (2015)

The temporal version of the pediatric sepsis biomarker risk model (tPERSEVERE) estimates the risk of a complicated course in children with septic shock based on biomarker changes from days 1 to 3 of septic shock. We validated tPERSEVERE performance i

Externí odkaz: https://doaj.org/article/95c06a372a3c4915afb2ad11bbc83c48

Zobrazit plný text záznamu

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021

Autor: Anne Zepeski, Catherine L. Hough, Wesley H. Self, Ian Jones, Amira Mohamed, Tresa McNeal, Samuel M. Brown, Shekhar Ghamande, Jennifer G. Wilson, Alexandra June Gordon, Eric A. Naioti, Manjusha Gaglani, Jay S. Steingrub, Steven Y. Chang, Natalie J. Thornburg, Yuwei Zhu, Adrienne Baughman, Mark W Tenforde, Matthew E. Prekker, Christopher J. Lindsell, William B. Stubblefield, Arnold S. Monto, Nida Qadir, James D. Chappell, Nicholas M. Mohr, Carolina Rivas, Sandra N. Lester, Abhijit Duggal, Ithan D. Peltan, Kevin W Gibbs, Jillian P. Rhoads, Jennifer R. Verani, Miwako Kobayashi, Hilary M. Babcock, Manish M. Patel, Arber Shehu, Emily T. Martin, Natasha B. Halasa, Laurence W. Busse, Megan M. Stump, Jennie H. Kwon, David J. Douin, Daniel J. Henning, Matthew C. Exline, Kelsey N Womack, Michelle N. Gong, Todd W. Rice, Samantha M. Olson, H. Keipp Talbot, Adam S. Lauring, Jonathan D Casey, Adit A. Ginde, Kimberly W. Hart, Heidi L Erickson, D. Clark Files, David N. Hager, Carlos G. Grijalva, Lisa Mills, Christopher Mallow, Akram Khan, Caitlin C Ten Lohuis

Publikováno v: Morbidity and Mortality Weekly Report

Three COVID-19 vaccines are authorized or approved for use among adults in the United States (1,2). Two 2-dose mRNA vaccines, mRNA-1273 from Moderna and BNT162b2 from Pfizer-BioNTech, received Emergency Use Authorization (EUA) by the Food and Drug Ad

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3695ec34b8521f85c10fe2b51a1b6080
https://doi.org/10.15585/mmwr.mm7038e1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání